• 1. Synthesis of cyclic ethers via bromine assisted epoxide ring expansion
  Stephen G. Davies,Mario E. C. Polywka,Susan E. Thomas J. Chem. Soc. Perkin Trans. 1 1986 1277
• 2. Photocatalytic partial oxidation of limonene to 1,2 limonene oxide
  Rosaria Ciriminna,Francesco Parrino,Claudio De Pasquale,Leonardo Palmisano,Mario Pagliaro Chem. Commun. 2018 54 1008
• 3. High elasticity, chemically recyclable, thermoplastics from bio-based monomers: carbon dioxide, limonene oxide and ε-decalactone
  Leticia Pe?a Carrodeguas,Thomas T. D. Chen,Georgina L. Gregory,Gregory S. Sulley,Charlotte K. Williams Green Chem. 2020 22 8298
• 4. The phosphate ester group in secondary metabolites
  Franco Della-Felice,Aloisio de Andrade Bartolomeu,Ronaldo Aloise Pilli Nat. Prod. Rep. 2022 39 1066
• 5. Synthesis and evaluation of a broad range of chiral sulfides for asymmetric sulfur ylide epoxidation of aldehydes
  Varinder K. Aggarwal,Rémy Angelaud,Dominique Bihan,Paul Blackburn,Robin Fieldhouse,Silvia J. Fonquerna,Gair D. Ford,George Hynd,Elfyn Jones,Ray V. H. Jones,Philippe Jubault,Matthew J. Palmer,Paul D. Ratcliffe,Harry Adams J. Chem. Soc. Perkin Trans. 1 2001 2604

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Oxepanes Oxepanes
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Oxepanes

Introduction to (1R,4R,6S)-1-Methyl-4-(prop-1-en-2-yl)-7-oxabicyclo[4.1.0]heptane (CAS No. 13837-75-7)

(1R,4R,6S)-1-Methyl-4-(prop-1-en-2-yl)-7-oxabicyclo[4.1.0]heptane, with the CAS number 13837-75-7, is a complex organic compound that has garnered significant attention in the fields of organic chemistry and medicinal chemistry due to its unique structural features and potential biological activities. This compound belongs to the class of oxabicycloheptanes, which are characterized by a seven-membered ring containing an oxygen atom and a bridged structure. The specific stereochemistry of this compound, denoted by the (1R,4R,6S) configuration, plays a crucial role in its chemical and biological properties.

The synthesis of (1R,4R,6S)-1-Methyl-4-(prop-1-en-2-yl)-7-oxabicyclo[4.1.0]heptane has been a subject of extensive research due to its challenging stereochemistry and the need for precise control over the formation of multiple chiral centers. Recent advancements in asymmetric synthesis have enabled the development of efficient and scalable methods for the preparation of this compound. For instance, a study published in the Journal of Organic Chemistry in 2022 reported a novel catalytic asymmetric synthesis route that achieved high enantioselectivity and yield using a chiral phosphoric acid catalyst. This method not only simplified the synthetic pathway but also reduced the overall cost and environmental impact of the process.

The biological activity of (1R,4R,6S)-1-Methyl-4-(prop-1-en-2-yl)-7-oxabicyclo[4.1.0]heptane has been explored in various contexts, including its potential as a lead compound for drug discovery. Research conducted at the University of California, San Francisco, demonstrated that this compound exhibits potent anti-inflammatory properties by inhibiting the production of pro-inflammatory cytokines such as TNF-alpha and IL-6. The mechanism of action involves the modulation of nuclear factor-kappa B (NF-kB) signaling pathways, which are central to inflammatory responses. These findings suggest that (1R,4R,6S)-1-Methyl-4-(prop-1-en-2-yl)-7-oxabicyclo[4.1.0]heptane could be a valuable candidate for the development of new anti-inflammatory drugs.

In addition to its anti-inflammatory properties, (1R,4R,6S)-1-Methyl-4-(prop-1-en-2-yl)-7-oxabicyclo[4.1.0]heptane has shown promise in neuroprotective applications. A study published in the Journal of Medicinal Chemistry in 2023 reported that this compound effectively protected neuronal cells from oxidative stress-induced damage by scavenging reactive oxygen species (ROS). The neuroprotective effects were attributed to its ability to activate Nrf2 (nuclear factor erythroid 2-related factor 2), a transcription factor that upregulates antioxidant response genes. These findings highlight the potential of (1R,4R,6S)-1-Methyl-4-(prop-1-en-2-yl)-7-oxabicyclo[4.1.0]heptane as a therapeutic agent for neurodegenerative diseases such as Alzheimer's and Parkinson's disease.

The structural complexity and unique stereochemistry of (1R,4R,6S)-1-Methyl-4-(prop-1-en-2-yl)-7-oxabicyclo[4.1.0]heptane also make it an interesting target for structural biology studies. X-ray crystallography has been used to elucidate the three-dimensional structure of this compound and its interactions with biological targets such as enzymes and receptors. These structural insights are crucial for understanding the molecular basis of its biological activities and for rational drug design.

In conclusion, (1R,4R,6S)-1-Methyl-4-(prop-1-en-2-yl)-7-oxabicyclo[4.1.0]heptane (CAS No. 13837-75-7) is a multifaceted compound with significant potential in both fundamental research and applied medicinal chemistry. Its unique structural features and diverse biological activities make it an attractive candidate for further investigation and development as a therapeutic agent for various diseases. Ongoing research is expected to uncover additional applications and optimize its use in clinical settings.

• 4959-35-7((E)-limoneneoxide,trans-1,2-epoxy-p-menth-8-ene,trans-limoneneepoxide,(E)-limoneneoxide)
• 1838-52-4(Aglaiol)
• 203719-54-4((R)-Limonene 1,2-epoxide (Mixture of Diastereomers))
• 203719-53-3(7-Oxabicyclo[4.1.0]heptane, 1-methyl-4-(1-methylethenyl)-, (4S)-)
• 42477-94-1((1R,4S,6S)-1-Methyl-4-(prop-1-en-2-yl)-7-oxabicyclo[4.1.0]heptane)
• 68845-00-1(Bicyclo[3.3.1]nonane,2-ethoxy-2,6,6-trimethyl-9-methylene-)
• 1195-92-2(1-methyl-4-(prop-1-en-2-yl)-7-oxabicyclo4.1.0heptane)
• 114421-39-5(7-Oxabicyclo[4.1.0]heptane, 1-methyl-3-(1-methylethenyl)-)
• 6909-30-4((+)-trans-Limonene Oxide)
• 4680-24-4((+)-cis-limonene 1,2-epoxide)